Bharat Parenterals Ltd vs Unjha Formulations Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 15, 2026

Key Highlights

The Latest Trading Price of Bharat Parenterals Ltd is ₹ 1252 as of 15 May 15:30 . The P/E Ratio of Bharat Parenterals Ltd changed from 9.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Unjha Formulations Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bharat Parenterals Ltd changed from ₹ 192 crore on March 2021 to ₹ 680.55 crore on March 2025 . This represents a CAGR of 28.80% over 5 yearsThe Market Cap of Unjha Formulations Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Bharat Parenterals Ltd for the Dec '25 is ₹ 66.52 crore as compare to the Sep '25 revenue of ₹ 68.15 crore. This represent the decline of -2.39% The revenue of Unjha Formulations Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Bharat Parenterals Ltd for the Dec '25 is ₹ 3.07 crore as compare to the Sep '25 ebitda of ₹ 4.35 crore. This represent the decline of -29.43% The ebitda of Unjha Formulations Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Bharat Parenterals Ltd changed from ₹ -8.84 crore to ₹ -9.67 crore over 7 quarters. This represents a CAGR of 5.26% The net profit of Unjha Formulations Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.6 % on March 2025 . This represents a CAGR of 13.46% over 3 yearsThe Dividend Payout of Unjha Formulations Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bharat Parenterals Ltd

Bharat Parenterals Limited was incorporated in September, 1992 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company on 09 July, 2016.
Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective from 28th June, 2022.

About Unjha Formulations Ltd

Unjha Formulations Limited was established in June, 1987 as a Partnership firm for manufacturing pharmaceutical formulations in the Mehsana district of Gujarat.
The Company is a pioneer in Isabgol (Psyllium) Formulation.
The Company is in service to Isabgol (Psyllium) Ayurvedic formulation profession. The company manufactures pharmaceutical formulations like liquids, powder, tablets, capsules, injectibles, etc.
It is one of the largest manufacturers of isabgul products in India.
The company's products are classified under two divisions -- human consumption and veterinary products. Its parent company M/S Urvesh Ltd. is 100% EOU is engaged in exporting of Isabol Husk & Isabgol Powder.

FAQs for the comparison of Bharat Parenterals Ltd and Unjha Formulations Ltd

Which company has a larger market capitalization, Bharat Parenterals Ltd or Unjha Formulations Ltd?

Market cap of Bharat Parenterals Ltd is 862 Cr while Market cap of Unjha Formulations Ltd is 9 Cr

What are the key factors driving the stock performance of Bharat Parenterals Ltd and Unjha Formulations Ltd?

The stock performance of Bharat Parenterals Ltd and Unjha Formulations Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Parenterals Ltd and Unjha Formulations Ltd?

As of May 15, 2026, the Bharat Parenterals Ltd stock price is INR ₹1252.05. On the other hand, Unjha Formulations Ltd stock price is INR ₹20.11.

How do dividend payouts of Bharat Parenterals Ltd and Unjha Formulations Ltd compare?

To compare the dividend payouts of Bharat Parenterals Ltd and Unjha Formulations Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.